These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 33916279)

  • 1. Clinical Significance of Tumor Microenvironment in Acral Melanoma: A Large Single-Institution Study of Caucasians.
    Borkowska AM; Szumera-Ciećkiewicz A; Chraszczewska M; Sokół K; Goryń T; Rutkowski PŁ
    J Clin Med; 2021 Apr; 10(7):. PubMed ID: 33916279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 expression in tumour-infiltrating lymphocytes is a poor prognostic factor for primary acral melanoma patients.
    Ren M; Dai B; Kong YY; Lv JJ; Cai X
    Histopathology; 2018 Sep; 73(3):386-396. PubMed ID: 29637587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of tumor PD-L1 expression combined with CD8
    Wang Q; Lou W; Di W; Wu X
    Int Immunopharmacol; 2017 Nov; 52():7-14. PubMed ID: 28846888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
    Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
    Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Difference in immunohistochemical findings among anti-PD-L1 antibodies and their relationships with CD4+ and CD8+ T cells in Japanese melanoma patients.
    Yoneta D; Kato J; Kamiya T; Horimoto K; Sato S; Sawada M; Minowa T; Hida T; Sugita S; Uhara H
    Int J Clin Oncol; 2022 Aug; 27(8):1364-1371. PubMed ID: 35650364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Significance of Programmed Death Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Axial Osteosarcoma.
    Liu P; Xiao Q; Zhou B; Dai Z; Kang Y
    World Neurosurg; 2019 Sep; 129():e240-e254. PubMed ID: 31128313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases.
    Berghoff AS; Ricken G; Widhalm G; Rajky O; Dieckmann K; Birner P; Bartsch R; Höller C; Preusser M
    Histopathology; 2015 Jan; 66(2):289-99. PubMed ID: 25314639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PD-L1, CD4+, and CD8+ Tumor-Infiltrating Lymphocytes (TILs) Expression Profiles in Melanoma Tumor Microenvironment Cells.
    Caraban BM; Matei E; Cozaru GC; Aşchie M; Deacu M; Enciu M; Bălţătescu GI; Chisoi A; Dobrin N; Petcu L; Gheorghe E; Hangan LT; Roșu MC; Orasanu CI; Nicolau AA
    J Pers Med; 2023 Jan; 13(2):. PubMed ID: 36836455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
    Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
    Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives Primarily from Functionally Anergic CD4
    Mattox AK; Lee J; Westra WH; Pierce RH; Ghossein R; Faquin WC; Diefenbach TJ; Morris LG; Lin DT; Wirth LJ; Lefranc-Torres A; Ishida E; Chakravarty PD; Johnson L; Zeng YC; Chen H; Poznansky MC; Iyengar NM; Pai SI
    Cancer Res; 2017 Nov; 77(22):6365-6374. PubMed ID: 28947422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of tumor infiltrating lymphocytes on first-line pembrolizumab efficacy in advanced non-small cell lung cancer.
    Kaira K; Yamaguchi O; Kawasaki T; Hashimoto K; Miura Y; Shiono A; Mouri A; Imai H; Kobayashi K; Yasuda M; Kagamu H
    Discov Oncol; 2023 Jan; 14(1):6. PubMed ID: 36662367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Impact of the Immune Microenvironment in Spinal Chordoma: Immunoscore as an Independent Favorable Prognostic Factor.
    Zou MX; Lv GH; Wang XB; Huang W; Li J; Jiang Y; She XL
    Neurosurgery; 2019 Jun; 84(6):E318-E333. PubMed ID: 30032257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.
    El-Guindy DM; Helal DS; Sabry NM; Abo El-Nasr M
    J Egypt Natl Canc Inst; 2018 Dec; 30(4):125-131. PubMed ID: 30337185
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical relevance and significance of programmed death-ligand 1 expression, tumor-infiltrating lymphocytes, and p16 status in sinonasal squamous cell carcinoma.
    Quan H; Yan L; Wang S; Wang S
    Cancer Manag Res; 2019; 11():4335-4345. PubMed ID: 31190998
    [No Abstract]   [Full Text] [Related]  

  • 16. Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases.
    Harter PN; Bernatz S; Scholz A; Zeiner PS; Zinke J; Kiyose M; Blasel S; Beschorner R; Senft C; Bender B; Ronellenfitsch MW; Wikman H; Glatzel M; Meinhardt M; Juratli TA; Steinbach JP; Plate KH; Wischhusen J; Weide B; Mittelbronn M
    Oncotarget; 2015 Dec; 6(38):40836-49. PubMed ID: 26517811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer.
    Zhang L; Wang XI; Ding J; Sun Q; Zhang S
    Ann Diagn Pathol; 2019 Jun; 40():143-151. PubMed ID: 31096176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of PD-L1 expression and tumor infiltrating lymphocytes in large cell neuroendocrine carcinoma of lung.
    Ohtaki Y; Kaira K; Atsumi J; Nagashima T; Kawashima O; Ibe T; Kamiyoshihara M; Onozato R; Fujita A; Yazawa T; Sugano M; Iijima M; Nakazawa S; Obayashi K; Kosaka T; Yajima T; Kuwano H; Shirabe K; Mogi A; Shimizu K
    Am J Transl Res; 2018; 10(10):3243-3253. PubMed ID: 30416665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Appraisal of clinicopathological prognosticators in advanced acral lentiginous melanoma with characterization of PD-L1 and CD8/CD4 immunoprofiles.
    Chuang IC; Jang CS
    Jpn J Clin Oncol; 2022 Sep; 52(9):975-981. PubMed ID: 35662346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy.
    Chen TW; Huang KC; Chiang SF; Chen WT; Ke TW; Chao KSC
    J Cancer Res Clin Oncol; 2019 Apr; 145(4):1043-1053. PubMed ID: 30874889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.